These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16749531)

  • 21. Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
    Zech SG; Carr M; Mohemmad QK; Narasimhan NI; Murray C; Rozamus LW; Dalgarno DC
    J Antibiot (Tokyo); 2011 Sep; 64(9):649-54. PubMed ID: 21792211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extraction of o-phenylphenol from silicone tubing by a sulfobutylether cyclodextrin formulation.
    Zimmerman JA; Ballard JM; Wang H; Wu A; Gallagher KA
    Int J Pharm; 2003 Nov; 267(1-2):113-20. PubMed ID: 14602389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation, structural determination, synthesis and quantitative determination of impurities in Intron-A, leached from a silicone tubing.
    Chan TM; Pramanik B; Aslanian R; Gullo V; Patel M; Cronin B; Boyce C; McCormick K; Berlin M; Zhu X; Buevich A; Heimark L; Bartner P; Chen G; Pu H; Hegde V
    J Pharm Biomed Anal; 2009 Feb; 49(2):327-32. PubMed ID: 19150187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and characterization of some potential impurities in ropinirole hydrochloride.
    Sahasrabuddhey B; Nautiyal R; Acharya H; Khyade S; Luthra PK; Deshpande PB
    J Pharm Biomed Anal; 2007 Mar; 43(4):1587-93. PubMed ID: 17207602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving the detection of degradants and impurities in pharmaceutical drug products by applying mass spectral and chromatographic searching.
    Freed AL; Kale U; Ando H; Rossi DT; Kingsmill CA
    J Pharm Biomed Anal; 2004 Jun; 35(4):727-38. PubMed ID: 15193717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategy for identification of leachables in packaged pharmaceutical liquid formulations.
    Pan C; Harmon F; Toscano K; Liu F; Vivilecchia R
    J Pharm Biomed Anal; 2008 Feb; 46(3):520-7. PubMed ID: 18180126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fundamentals of freeze-drying.
    Nail SL; Jiang S; Chongprasert S; Knopp SA
    Pharm Biotechnol; 2002; 14():281-360. PubMed ID: 12189727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
    Santana H; García G; Vega M; Beldarraín A; Páez R
    PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term stabilization of a new freeze-dried and albumin-free formulation of recombinant human interferon alpha 2b.
    Ruiz L; Reyes N; Sotolongo J; Aroche K; Aldana R; Báez R; Hardy E
    PDA J Pharm Sci Technol; 2006; 60(1):72-8. PubMed ID: 17089680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of LC detection methods in the investigation of non-UV detectable organic impurities in a drug substance.
    McCrossen SD; Bryant DK; Cook BR; Richards JJ
    J Pharm Biomed Anal; 1998 Jul; 17(3):455-71. PubMed ID: 9656157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
    Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
    Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
    Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
    J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
    Liu DQ; Chen TK; McGuire MA; Kord AS
    J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the structures of photodegradation impurities and pathways of photodegradation of cilnidipine by liquid chromatography/Q-Orbitrap mass spectrometry.
    Zeng H; Wang F; Zhu B; Zhong W; Shan W; Wang J
    Rapid Commun Mass Spectrom; 2016 Aug; 30(15):1771-8. PubMed ID: 27426453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LC determination of glimepiride and its related impurities.
    Khan MA; Sinha S; Vartak S; Bhartiya A; Kumar S
    J Pharm Biomed Anal; 2005 Oct; 39(5):928-43. PubMed ID: 16040224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug.
    Peng Y; Luo J; Lu Q; Chen X; Xie Y; Chen L; Yang W; Du S
    J Pharm Biomed Anal; 2009 Apr; 49(3):828-32. PubMed ID: 19167183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and characterization of unknown degradation impurities in beclomethasone dipropionate cream formulation using HPLC, ESI-MS and NMR.
    Sambandan E; Kathavarayan T; Sellappan S; Shiea J; Ponnusamy VK
    J Pharm Biomed Anal; 2019 Apr; 167():123-131. PubMed ID: 30771645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural identification and characterization of potential degradants of zotarolimus on zotarolimus-coated drug-eluting stents.
    Chen Q; Zielinski D; Chen J; Nowak S; Zhou CC
    J Pharm Biomed Anal; 2009 Dec; 50(5):778-86. PubMed ID: 19581067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.